The Importance of Cell Media Analysis in Upstream Bioprocess Development

The Importance of
As it is with so many things in life, how we begin often sets the tone for the entire journey. Bioproduction endeavors are no different. Using robust reagents and developing reproducible procedures at the early stages of your bioprocess is critical to producing a safe and efficacious final product. Upstream process scientists are constantly trying to improve parameters such as growth conditions, media analysis, and optimizing cell lines to ease the burden on downstream purification steps. Determining the best way to begin your bioproduction journey takes a lot of experience and can often seem daunting. However, in this presentation, our panelists will tell us what’s necessary for those initial successful steps.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Decoding Antibody Discovery—The Future of Next-Gen Biologics

Antibodies have established themselves as one of the most important classes within the biologics space, and developing these therapeutics requires a series of successful decisions throughout the early-discovery process.
Watch Now

What 2023 Holds for Cell and Gene Therapy

As we look ahead to 2023, the field of cell and gene therapy is on the brink of some major developments and milestones.
Watch Now

Contamination control strategies: How to achieve faster, easier process monitoring

A contamination control strategy (CCS) considers microbiological monitoring of assessed points and is a fundamental aspect of managing risks associated with contamination.
Watch Now

The Evolving Role of BRCA Testing in Ovarian Cancer

captodayonline

Webinar presenters Dana Chase, MD, FACOG,Assistant Professor, Division of Gynecologic Oncology University of Arizona College of Medicine, Phoenix, AZ, Creighton University School of Medicine at St. Joseph’s Hospital, Phoenix, AZ, Gynecologic Oncologist, Arizona Oncology, and John Longshore, PhD, FACMG, Director, Molecular Pathology, Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, discuss the link between molecular profiles and disease pathogenesis in ovarian cancer, the clinical significance of PARP inhibition in BRCA1 and/or 2–mutated ovarian cancer, the testing process for BRCA mutations, and the evolving paradigms in tumor and germline BRCA testing in ovarian cancer.
Watch Now

Spotlight

resources